ABSTRACT
Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4,2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.
ABSTRACT
Objective To investigate the usage of Shuxuening Injection in Chuzhou Hospital of Traditional Chinese and Western Medicine (hereinafter referred to as our hospital); To promote clinical rational usage of Shuxuening Injection. Methods A retrospective study was conducted to 297 cases of using Shuxuening Injection in our hospital from January 2016 to June 2016. Results In the 297 cases, 58.9% patients were over 60 years old, and indication coincidence rate of Shuxuening Injection was 52.2%. 91.2% single dose met the instructions and 6.7%solvent use met instructions. Shuxuening Injection in the joint medication also had irrational usage phenomenon. Conclusion There is irrational usage of Shuxuening Injection in our hospital, especially in indication and solvent.
ABSTRACT
OBJECTIVE:To provide reference for clinical rational drug use. METHODS:Combined with bacterial drug resis-tance monitoring data in our hospital in 2014,the varieties,the amount of antibacterial drug,DDDs and other index were analyzed retrospectively for the same period. RESULTS:The detection rate of Gram-negative bacteria (79.27%) was higher than that of Gram-positive bacteria (20.73%);the most common Gram-negative bacilli and Gram-positive cocci were Escherichia coli (38.62%) and Staphylococcus aureus (5.22%). Pseudomonas aeruginosa and Stenotrophomonas maltophilia were the most com-mon non-fermentation bacteria;Main Gram positive bacteria were most sensitive to vancomycin,tigecycline and furadantin,etc. Main Gram-negative bacteria were most sensitive to imipenem,ertapenem,etc. Top 3 antibacterial drug in the list of DDDs were Levofloxacin injection,Cefazolin injection,Cefoperazone/sodium sulbactam for injection. CONCLUSIONS:Third generation of cephalosporins are used frequently in our hospital,which is a major cause of ESBLs producing and drug resistance,bacterial drug resistance monitoring and early warning data has played a positive role on guiding reasonable application of antibacterial drug in our hospital.